Selected article for: "effective vaccine and host cell"
Author: Chauhan, Gaurav; Madou, Marc J.; Kalra, Sourav; Chopra, Vianni; Ghosh, Deepa; Martinez-Chapa, Sergio O.
Title: Nanotechnology for COVID-19: Therapeutics and Vaccine Research
  • Cord-id: 85zogvak
  • Document date: 2020_6_22
    • ID: 85zogvak
    Snippet: [Image: see text] The current global health threat by the novel coronavirus disease 2019 (COVID-19) requires an urgent deployment of advanced therapeutic options available. The role of nanotechnology is highly relevant to counter this “virus” nano enemy. Nano intervention is discussed in terms of designing effective nanocarriers to counter the conventional limitations of antiviral and biological therapeutics. This strategy directs the safe and effective delivery of available therapeutic opti
    Document: [Image: see text] The current global health threat by the novel coronavirus disease 2019 (COVID-19) requires an urgent deployment of advanced therapeutic options available. The role of nanotechnology is highly relevant to counter this “virus” nano enemy. Nano intervention is discussed in terms of designing effective nanocarriers to counter the conventional limitations of antiviral and biological therapeutics. This strategy directs the safe and effective delivery of available therapeutic options using engineered nanocarriers, blocking the initial interactions of viral spike glycoprotein with host cell surface receptors, and disruption of virion construction. Controlling and eliminating the spread and reoccurrence of this pandemic demands a safe and effective vaccine strategy. Nanocarriers have potential to design risk-free and effective immunization strategies for severe acute respiratory syndrome coronavirus 2 vaccine candidates such as protein constructs and nucleic acids. We discuss recent as well as ongoing nanotechnology-based therapeutic and prophylactic strategies to fight against this pandemic, outlining the key areas for nanoscientists to step in.

    Search related documents:
    Co phrase search for related documents
    • action site and acute respiratory syndrome: 1, 2, 3, 4
    • action site and ade antibody dependent enhancement: 1
    • activation motif and acute respiratory syndrome: 1
    • activation motif and adhesion molecule: 1
    • activator protein and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6
    • activator protein and acute inflammation: 1, 2, 3
    • activator protein and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • active moiety and acute respiratory syndrome: 1, 2, 3
    • acute ards respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute ards respiratory distress syndrome and ade antibody dependent enhancement: 1, 2
    • acute ards respiratory distress syndrome and adhesion molecule: 1, 2, 3, 4, 5, 6
    • acute infectious disease and adaptive immune response: 1, 2, 3
    • acute infectious disease and adhesion molecule: 1
    • acute inflammation and adaptive immune response: 1, 2, 3, 4
    • acute inflammation and ade antibody dependent enhancement: 1
    • acute inflammation and adhesion molecule: 1, 2, 3, 4, 5, 6
    • acute myeloid leukemia and adhesion molecule: 1, 2
    • acute respiratory syndrome and ade antibody dependent enhancement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and adhesion molecule: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25